Organization (Academic)
University of Groningen
ClinicalTrials.gov lists University of Groningen as lead sponsor of 22 trials. It has 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers University of Groningen: 22 lead-sponsored trials and 1 legal-entity registration.
Disease areas (68)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 3 |
| Diabetes Mellitus, Type 2 | 3 |
| Disease | 3 |
| HIV Infections | 3 |
| Malnutrition | 3 |
Showing 5 of 68 disease areas.
Trials by start year as sponsor or collaborator (17)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 6 |
| 2023 | 6 |
| 2022 | 7 |
| 2021 | 4 |
| 2020 | 2 |
| 2019 | 5 |
| 2018 | 6 |
| 2017 | 6 |
Showing 10 of 17 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (1)
| Drug | Trials |
|---|---|
| Tryptophan | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 60% hit target (n=5) | 40% on time (n=5) |
Journals published in (110)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| BMJ open | 7 |
| Lancet (London, England) | 7 |
| BMC psychology | 5 |
| The New England journal of medicine | 5 |
| PLoS medicine | 4 |
Showing 5 of 110 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 79 | 18 | 2025-12-23 |
Organization relationships (134)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University Medical Center Groningen | Co sponsors trial with | 3 |
| Bekasi City Public Hospital | Co sponsors trial with | 2 |
| Assistance Publique – Hôpitaux de Paris | Co sponsors trial with | 2 |
| University Medical Center Utrecht | Co sponsors trial with | 2 |
| Hospices Civils de Lyon | Co sponsors trial with | 1 |
Showing 5 of 134 relationships.
Latest dated events (147)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-10-14 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-04-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 147 events.
Biomarker capability evidence (28)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| IDS | Trial collaborator | Named in trial inclusion criteria |
| PTBP1 | Trial collaborator | Named in trial inclusion criteria |
| PTBP2 | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial exclusion criteria |
Showing 5 of 28 evidence rows.
Biomarkers this organization publishes on (1,956)
Shown in this order: most publications first.
Showing 5 of 1,956 biomarkers.
On Scientist.com
University of Groningen is listed as a research supplier in the Scientist.com network.
University of Groningen provides academic research and collaboration.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with University of Groningen on Scientist.com
For prices, more details, or to contact University of Groningen, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.